Open Access
Editorial
Table 3
GLP-1RA drugs characteristics.
| Drug | Type of receptor agonism | Elimination half-life | Dose interval | Trade name |
|---|---|---|---|---|
| Liraglutide | GLP-1 | 12.6–14.3 h | Once daily | Victoza, Saxenda |
| Tirzepatide | GLP-1 and GIP | 4.2–6.1 days | Once weekly | Mounjaro |
| Dulaglutide | GLP-1 | 4.7–5.5 days | Once weekly | Trulity |
| Samaglutide | GLP-1 | 5.7–6.7 days | Once weekly | Ozempic |
GLP-1: Glucagon-like peptide-1; GIP: glucose-dependent insulinotropic peptide.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.